Hutchmed (china) Share Discussion Threads

[steeplejack] 13/3/2017 23:36

Panmure Gordon 2900p targetDr Mike Mitchell, an analyst at broker Panmure Gordon, thinks they can go further: "We believe the business has started to demonstrate the quality of its strategy and ability to execute in one of the most challenging areas of medicine with some potentially transformational programmes, covering 8 drug candidates now in 30 active clinical trials. "With today's announcement, we consider our investment thesis for Hutchison China MediTech not only affirmed but also reinforced," he says. Still rating Chi-Med shares a 'buy', Mitchell ramps up his price target by 9% from 2,656p to 2,900p, which, if reached, would be a record high.US has woken up with sizeable volume on NASDAQ.This stock is well held with a blue chip list of holders,Schroders,Prudential,Baillie Gifford and Mark Slater's fund has a short 6% .Matthew International have been adding .Oh and the Investors Chronicle recommended buy at the end of last week.Finally things are bubbling.

[miti 1000] 13/3/2017 11:12

Quite a few presentations in the US over the next few weeks. Lets hope they finally wake up.
Davey, are you happy with those peak CRC revenue figures?

[nerdofsteel] 13/3/2017 11:01

This will be a $10bn mcap company within the next 5-10 years IMO

Their biggest strength is the consistency of their growth and execution

They have a clear strategy, do not deviate from it, and always deliver what they promise.

[steeplejack] 13/3/2017 09:39

All this, and the proceeds of the Nasdaq listing, mean cash and available resources at year-end were $173.7 million, up by about $135 million, despite the sharp increase in clinical investment, and expected to be sufficient to cover development needs well into 2019. This financial strength has also allowed for re-negotiation of the collaboration agreement with AstraZeneca AB (publ) ("AstraZeneca"), enabling Chi-Med to take a greater share in the potential long-term economic value of savolitinib in return for increasing its investment.Over fifteen years of consistent commercial and scientific strategies, along with a pragmatic approach to finance and risk management, has led Chi-Med to today's position. The first wave of new drug candidates, led by fruquintinib, and including savolitinib, sulfatinib and epitinib, are progressing towards potential registration and launch in major markets. The second wave of novel drug candidates including theliatinib, HMPL-523, HMPL-689 and HMPL-453 are now mostly in proof-of-concept studies. In addition Chi-Med's discovery platform is generating a third wave of innovation with a strong immuno-oncology focus. Combining this innovation pipeline with a valuable China marketing and distribution platform, important international partners and a robust cash position lead Chi-Med to view the future with confidence."

[nerdofsteel] 10/3/2017 08:30

Great updates today

FY16 results on Monday at 07:00
Analyst presentation at 09:00
U.S. Analyst presentation at 08:00 EST / 13:00 GMT

[nerdofsteel] 08/3/2017 07:25

Yes, read that on the train last night

Here is the online version

[storm8] 07/3/2017 16:46

There is an article in tonight's London Evening Standard confirming the progress Chi Med have made and the Phase III trials of the cancer drug Fruquintinib, and probably one of the drivers for the >3% rise in share price today.
I hold and will continue to do so.

[nerdofsteel] 07/3/2017 13:55

Edison update today



Regarding NASDAQ and AIM SP's there is an ability for London Market-makers and New York Market-makers to cross-trade so buying shares in London for example, may mean a trade occurs on NASDAQ (offmarket if out of hours). The Company explains more on their website and comments that this arrangement ensures pricing parity, or prevents prices form getting too out of sync.

I agree about the lack of takeover prospects steeple, which is a pity, but I still think we will be a $10bn mcap Company within the next 5 years IMO

[steeplejack] 07/3/2017 08:22

Nonetheless,London is ignoring the rally(on good volume)in New York.You can buy stock,500 shares at 2325p this morning and cheekily,they'll bid 150p lower than the New York close at 2275 for the same.Odd to say the least.I wonder whether the company might do a GW Pharma and dump this AIM listing.

[steeplejack] 06/3/2017 23:02

Up to £24-25 equivalent bid in NYSE....

[steeplejack] 06/3/2017 19:37

Even when things are a bit rough,biotechs invariably offer the chance of a takeover.Look at Ariad Pharma,totally bombed out and priced at a couple of bucks some two years back but recently taken out by Takeda at 24 dollars.Here,we have the opposite,unequivocally excellent prospects but no possibility of that potential attracting a predator and I suggest that means Chi-med is unlikely to become overvalued.Share price appreciation will be hard won until the company adopts a progressive dividend policy.

[nerdofsteel] 05/3/2017 16:41

The longer the price remains stagnant the sharper the rise will be IMO

The market can ignore the end of Fruquintinib Phase III and may ignore the NDA in China shortly but there will now be fairly regular material news over the next few years as the pipeline is very mature.

I can't see how all of the data and all of the news can simply be cast aside. Maybe the U.S. market isn't interested in anything but the financials?

I regularly see U.S. Biotech rising 30% + on PIII completions and NDA's.

It seems our U.S. IR & PR people The Trout Group need to do even more to get our name around Specialist Biotech Investors

[miti 1000] 03/3/2017 15:49

Matt , sounds like you have already dumped it ?

[steeplejack] 03/3/2017 14:40

This stock typically trades on spread of around 3% in the UK and the US.Compare that with Shire which trades on a very tight spread .Ok,you can deal well inside the quote but you're still ceding a lot of flexibility to the marketmaker and in thin markets that's off-putting.The US hasn't embraced the significance of this clinical result by all accounts.The prospects here are excellent but the stock continues to labour.

[jaf1969] 03/3/2017 13:08

Unable to get a quote - are the mm short of stock?

[nerdofsteel] 03/3/2017 11:20

the AGM is going to be a great event this year

[nerdofsteel] 03/3/2017 11:20

The ADR's languish well below their issue price a year ago

Let's hope NASDAQ gives this fantastic news the credit it deserves

This is just the start, loads more material news due, milestone payments, plus all of this still to some in the next few weeks:-

Savolitinib Phase III in c-Met-driven PRCC. - will include large up-front Milestone payment
Epitinib Phase II/III in first-line patients with EGFR-mutant NSCLC with brain metastasis.
Savolitinib Phase III in combination with Tagrisso® (osimertinib) in second-line NSCLC (T790M-/c-Met+).
Fruquintinib NDA in China by mid 2017
$40m dividend due from Commercial JV by end June

[miti 1000] 03/3/2017 07:26

Fantastic news....period!!

[nerdofsteel] 03/3/2017 07:19

A big day, our first ever Phase III study completed with headline Results

Our first ever NDA is on its way

Today's announcement is significant and material

[nerdofsteel] 13/2/2017 10:20

Lots of extremely material news to come between now and mid April:-

Publishing data on 4 drug candidates in 5 Phase Ib-III studies:
Major/Material Savolitinib Phase II data in PRCC.
Epitinib Phase Ib data in NSCLC with brain metastasis - 6th Dec RNS
Fruquintinib Phase II data in third-line NSCLC - 6th Dec but no RNS
Sulfatinib Phase II data in pancreatic and extra-pancreatic NET.
Major/Material Fruquintinib Phase III top-line data in third-line or above colorectal cancer – potential NDA submission in mid-2017.

Likely to initiate three pivotal registration trials on two further drug candidates:
Savolitinib Phase III in c-Met-driven PRCC.
Epitinib Phase II/III in first-line patients with EGFR-mutant NSCLC with brain metastasis.
Savolitinib Phase III in combination with Tagrisso® (osimertinib) in second-line NSCLC (T790M-/c-Met+).

[nerdofsteel] 17/1/2017 11:58

Great news about Mr Carter - his skills gained at Gilead and GSK appear to be based on the commercialisation of drug candidates - he is surely a great asset as we come close to our first ever NDA and subsequent approvals. He has Asia experience too....

[nerdofsteel] 16/1/2017 13:03

hi mastermatto, no, I only have the detail that all of the following will be released or performed by April, based on the fact they stated in August 2016 the following would occur in the next 6 - 9 months

Publishing data on 4 drug candidates in 5 Phase Ib-III studies:
Savolitinib Phase II data in PRCC.
Epitinib Phase Ib data in NSCLC with brain metastasis
Fruquintinib Phase II data in third-line NSCLC
Sulfatinib Phase II data in pancreatic and extra-pancreatic NET.
Fruquintinib Phase III top-line data in third-line or above colorectal cancer – potential NDA submission in mid-2017.
Likely to initiate three pivotal registration trials on two further drug candidates:
Savolitinib Phase III in c-Met-driven PRCC.
Epitinib Phase II/III in first-line patients with EGFR-mutant NSCLC with brain metastasis.
Savolitinib Phase III in combination with Tagrisso® (osimertinib) in second-line NSCLC (T790M-/c-Met+).

Plenty of news today however including one of the above milestones

[mastermatto] 13/1/2017 11:59

Does anyone have any date when clinical trail results are going to be released?

I would like to see the pipeline for next 6 months.